News

Apexian Pharmaceuticals Announces FDA Agreement For Inclusion of Chemotherapy Induced Peripheral Neuropathy (CIPN) Indication Under Currently Approved IND

Indianapolis, IN – July 13, 2017 – Apexian Pharmaceuticals, a clinical stage biotechnology company developing novel compounds to treat cancer, today announced that it has received FDA agreement that the currently approved IND can be used to examine Chemotherapy Induced Peripheral Neuropathy (CIPN) as an indication in addition to its anti-tumor effects. APX3330, the lead molecule for Apexian has a dual biological role through the...

Apexian Pharmaceuticals licenses IU discoveries

INDIANAPOLIS, IN-- Apexian Pharmaceuticals Inc., a biotechnology company focused on developing novel compounds to treat cancer, has licensed all technology discovered in Mark Kelley's laboratory at the Indiana University School of Medicine. Read story on Indiana University website Indiana University Research and Technology Corp., which protects, markets and licenses intellectual property developed at IU so it can be commercialized by industry, issued the license. It allows...

Kelley presented Bantz-Petrinio Research award

Mark R. Kelley, PhD, was awarded the 2017 Bantz-Petronio Translating Research into Practice Award in recognition of his exemplary translational research in the area of cancer. In 2013 Former Chancellor Charles Bantz and Dr. Sandra Petronio established the Bantz-Petronio Translating Research into Practice Award because translational work is core to the schools of IUPUI. The award recognizes outstanding faculty research that is interdisciplinary and/or cross-disciplinary,...